GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
25 1월 2024 - 6:30AM
GeneDx, a leader in delivering improved health outcomes through
genomic and clinical insights, today announced that, effective as
of January 23, 2024, the compensation committee of GeneDx’s board
of directors granted newly hired employees 106,030 restricted stock
units (“RSUs”) as inducements material to each employee entering
into employment with GeneDx. The RSUs were granted under GeneDx’s
2023 Equity Inducement Plan and in accordance with Nasdaq Listing
Rule 5635(c)(4).
The inducement RSUs will vest in equal annual installments over
the four-year period following the grant date, subject to the
employee’s continued service with the Company on each applicable
vesting date.
Each RSU represents a contingent right to receive 1 share of the
Issuer's Class A Common Stock upon settlement. Typically, upon full
vesting, shares are sold to cover tax withholding obligations in
connection with the vesting and settlement of RSUs and funded by a
"sell to cover" transaction. This does not represent a
discretionary transaction by the Reporting Person.
About GeneDx
GeneDx (Nasdaq: WGS) delivers personalized and actionable health
insights to inform diagnosis, direct treatment and improve drug
discovery. The company is uniquely positioned to accelerate the use
of genomic and large-scale clinical information to enable precision
medicine as the standard of care. GeneDx is at the forefront of
transforming healthcare through its industry-leading exome and
genome testing and interpretation, fueled by one of the world’s
largest, rare disease data sets. For more information, please visit
www.genedx.com and connect with us on LinkedIn, Facebook, Twitter
and Instagram.
GeneDx Investor Relations Contact:Investors@GeneDx.com
GeneDx Media Contact:Press@GeneDx.com
GeneDx (NASDAQ:WGS)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
GeneDx (NASDAQ:WGS)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024